Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
$LYEL
Sector
Primary listing
Employees
300
Headquarters
Website
LYEL Metrics
BasicAdvanced
$334M
-
-$23.52
-0.20
-
Price and volume
Market cap
$334M
Beta
-0.2
52-week high
$19.45
52-week low
$7.65
Average daily volume
55K
Financial strength
Current ratio
7.647
Quick ratio
7.5
Long term debt to equity
15.588
Total debt to equity
18.435
Profitability
EBITDA (TTM)
-194.868
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-552,328.33%
Operating margin (TTM)
-351,916.67%
Management effectiveness
Return on assets (TTM)
-25.39%
Return on equity (TTM)
-76.59%
Valuation
Price to revenue (TTM)
4,081.729
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-1.424
Free cash flow yield (TTM)
-70.23%
Free cash flow per share (TTM)
-12.207
Growth
Revenue change (TTM)
11.11%
Earnings per share change (TTM)
41.75%
3-year revenue growth (CAGR)
-88.73%
3-year earnings per share growth (CAGR)
6.49%
Bulls say / Bears say
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 on April 15, 2025, which will allow more frequent discussions with regulators and recognizes its potential to address unmet needs in relapsed/refractory large B-cell lymphoma (GlobeNewswire).
As of March 31, 2025, Lyell reported cash, cash equivalents, and marketable securities totaling $330.1 million, offering sufficient capital to fund operations and reach multiple clinical milestones through 2027 (SEC 8-K).
The company remains on schedule to start the pivotal PiNACLE trial of LYL314 for third- or later-line treatment by mid-2025 and a second pivotal trial in the second-line setting by early 2026, reflecting disciplined progress of its main program (GlobeNewswire).
Lyell has received a notice from Nasdaq that it is not in compliance with the minimum bid price rule, as its shares closed below $1.00 for 33 consecutive business days. Lyell must regain compliance by July 22, 2025, or it could face delisting proceedings (TechDows).
Cash, cash equivalents, and marketable securities fell to about $297 million as of June 30, 2025, from $330.1 million on March 31, 2025, highlighting a significant cash burn rate that could limit Lyell’s financial runway to mid-2027 if not addressed (GlobeNewswire).
Lyell has discontinued its LYL119 solid tumor CAR T-cell program to focus on LYL314, which reduces pipeline diversification and raises execution risk by concentrating primarily on one lead asset (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $334M as of October 16, 2025.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of October 16, 2025.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.2. This means that it has an inverse relation to market volatility.